Welcome to our dedicated page for INVO Fertility SEC filings (Ticker: IVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
INVO Fertility, Inc. filings document the regulatory record of a Nasdaq-listed fertility-services company with clinic operations, INVOcell device activities and securities registered under the Exchange Act. Its recent 8-K reports cover material events including Nasdaq listing-rule notices, amendments to its articles of incorporation, a completed reverse stock split, authorized-share changes and material agreements tied to clinic acquisitions.
Proxy statements and shareholder-vote disclosures address governance matters, auditor ratification, warrant-related share issuance proposals and capital-structure approvals. Registration statements describe securities offerings and related risk, capitalization and corporate-information disclosures, while late-filing notices document the timing and accounting-related status of periodic reporting obligations.
INVO Fertility, Inc. notifies the SEC of a late Form 10-Q filing for the period ended March 31, 2026. The company says the Form 10-Q cannot be filed without unreasonable effort because its Annual Report on Form 10-K for the year ended December 31, 2025 is not yet complete following a change in its independent registered public accounting firm. Management states the new audit firm requires additional time to complete audit procedures and review complex technical accounting matters; the company is working to complete both filings as promptly as practicable.
INVO Fertility, Inc. amendment to a joint Schedule 13G/A discloses that Armistice Capital, LLC and Steven Boyd report beneficial ownership of 371,562 shares of Common Stock, representing 9.99% of the class. The filing states Armistice Capital has shared voting and dispositive power over those shares and that the Master Fund is the direct holder; the Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital. The filing is signed by Steven Boyd and dated 05/15/2026.
INVO Fertility, Inc. disclosed that Nasdaq notified the company on April 23, 2026 that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it did not timely file its Form 10‑K for the year ended December 31, 2025. The 2025 Annual Report was due April 15, 2026. The notice has no immediate effect on the Nasdaq Capital Market listing, and the shares continue to trade under the symbol IVF.
The company has 60 days from the notice date to submit a compliance plan and may receive up to 180 days from the report’s due date, or until October 13, 2026, to regain compliance if Nasdaq accepts the plan. INVO attributes the delay to additional review of complex accounting matters, including tax provision, warrant accounting, and variable interest entity accounting, and states it intends to file the Annual Report as promptly as possible.
Glenbrook Capital Management reports beneficial ownership of 134,515 shares of INVO Fertility, Inc. common stock, representing 8.33% of the class based on 1,615,419 shares outstanding as disclosed in the issuer's March 25, 2026 press release. The Schedule 13G states the position is held with shared voting and dispositive power and is filed by Glenbrook as a Nevada corporation. The filing is signed by Richard Rudgley on behalf of Glenbrook Capital Management.
INVO Fertility, Inc. notified the SEC it cannot file its Annual Report on Form 10-K for the year ended December 31, 2025 on time because it needs additional time to finalize financial statements and complete review of certain tax-related matters. The company expects to file within the 15-calendar-day extension period.
INVO Fertility, Inc. implemented a 1-for-5 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 27, 2026. Every 5 issued and outstanding shares were reclassified into 1 share, with no change to par value.
The company proportionately adjusted its capital structure so that it now has 50,000,000 authorized shares of common stock, and approximately 1,615,419 shares of common stock issued and outstanding immediately after the split. Outstanding options, warrants and equity plan reserves were also adjusted proportionately.
No fractional shares were issued; registered holders were rounded up to the next whole share, while beneficial holders in street name receive cash for fractional interests as determined by their brokers. The stock continues to trade on the Nasdaq Capital Market under the symbol IVF, with a new CUSIP number 44984F880.
INVO Fertility, Inc. closed its acquisition of Indiana-based fertility clinic Family Beginnings P.C. through subsidiary Wood Violet Fertility LLC. Buyer acquired the clinic’s non-medical assets and an affiliated professional corporation purchased the medical assets under related asset purchase agreements.
The combined consideration included cash at closing and 400 shares of Series D Non-Voting Convertible Preferred Stock issued to the seller. INVO also entered into a 10-year Management Services Agreement with a Florida professional corporation to provide management and operational support services for the practice.
To support operations, INVO’s subsidiary signed a lease for 4,387 rentable square feet in Indianapolis, with initial annual base rent of $132,398.61 and 2% annual increases starting in month sixteen. INVO created a new Series D Preferred class, authorizing 4,000 shares with a $1,000 stated value each, convertible into common stock at an initial price of $1.20 per share, subject to a 4.99% (or up to 9.99% on election) beneficial ownership cap.
INVO Fertility, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 602,965 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing states Armistice Capital exercises shared voting and dispositive power over these shares.
The schedule explains the shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager; Mr. Boyd is managing member of Armistice Capital. The Master Fund is identified as the direct holder and has the right to receive dividends or sale proceeds.
INVO Fertility, Inc. is registering for resale up to 9,467,456 shares of common stock issuable upon exercise of an Inducement Warrant held by Armistice Capital Master Fund Ltd. The warrant carries a $1.59 per share exercise price, and INVO may receive up to $15,053,255 if it is fully exercised.
INVO will not receive any proceeds from Armistice’s resale of shares, only from warrant exercises. The company plans to use any net proceeds primarily to acquire additional fertility clinics and related businesses, fund capital expenditures, and support working capital and general corporate purposes.
Armistice’s warrant is subject to a 9.99% beneficial ownership limitation, and INVO’s common stock traded at $1.37 per share on Nasdaq on January 30, 2026. The prospectus warns that issuance and resale of these shares could dilute existing holders and pressure the stock price.